根据2021年WHO分类系统对弥漫性胶质瘤进行基于影像与基于病理的生存分层比较
本研究纳入癌症基因组图谱141例(训练集)和峨山医疗中心131例(验证集)弥漫性胶质瘤患者,由两名神经放射科医师分析术前CT和MRI,按影像表型将肿瘤分为5个影像风险亚组并归为3个影像风险组,比较其与病理诊断的生存分层效能。结果显示影像分层对无进展生存和总生存均有分层作用(P<0.001),预测1年和5年无进展生存的AUC分别为0.787和0.823,与病理预测的0.785和0.837相似。
要点
- 影像可将弥漫性胶质瘤分为5个风险亚组并归为3个影像风险组,对总生存和无进展生存均有分层作用(P<0.001)。
- 影像风险组预测1年和5年无进展生存的AUC分别为0.787和0.823,与病理预测的0.785和0.837相似。
- 结合临床预测因子后,影像模型预测1年和3年无进展生存的AUC为0.813和0.921,与病理模型的0.839和0.889相似。
核心结论
- 根据2021年WHO分类的影像生存分层与病理生存分层表现相似,尤其在预测无进展生存方面。
研究设计与样本
- 研究纳入癌症基因组图谱弥漫性胶质瘤141例(训练集)和峨山医疗中心131例(验证集),由两名神经放射科医师分析术前CT和MRI进行影像风险分组,以病理诊断和生存数据为参考进行比较。
关键影像表现/征象
- 影像风险亚组1对应少突胶质瘤、异柠檬酸脱氢酶(IDH)突变且1p19q共缺失;亚组2和3对应星形细胞瘤、IDH突变;亚组4和5对应胶质母细胞瘤、IDH野生型。
- 影像风险分组基于已知影像表型(如T2/FLAIR不匹配)将肿瘤归为5个风险亚组并重新归为3个影像风险组。
诊断标准与关键数值
- 影像风险组1对应风险亚组1,提示少突胶质瘤、IDH突变、1p19q共缺失。
- 影像风险组2对应风险亚组2和3,提示星形细胞瘤、IDH突变。
- 影像风险组3对应风险亚组4和5,提示胶质母细胞瘤、IDH野生型。
- 影像风险组预测1年无进展生存的AUC为0.787,预测5年无进展生存的AUC为0.823。
- 病理预测1年和5年无进展生存的AUC分别为0.785和0.837;影像模型联合临床预测因子预测1年和3年无进展生存的AUC为0.813和0.921,病理模型为0.839和0.889。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Imaging-based survival stratification of patients with gliomas is important for their management, and the 2021 WHO classification system must be clinically tested. The aim of this study was to compare integrative imaging- and pathology-based methods for survival stratification of patients with diffuse glioma.
MATERIALS AND METHODS: This study included diffuse glioma cases from The Cancer Genome Atlas (training set: 141 patients) and Asan Medical Center (validation set: 131 patients). Two neuroradiologists analyzed presurgical CT and MRI to assign gliomas to five imaging-based risk subgroups (1 to 5) according to well-known imaging phenotypes (e.g., T2/FLAIR mismatch) and recategorized them into three imaging-based risk groups, according to the 2021 WHO classification: group 1 (corresponding to risk subgroup 1, indicating oligodendroglioma, isocitrate dehydrogenase [IDH]-mutant, and 1p19q-co-deleted), group 2 (risk subgroups 2 and 3, indicating astrocytoma, IDH-mutant), and group 3 (risk subgroups 4 and 5, indicating glioblastoma, IDHwt). The progression-free survival (PFS) and overall survival (OS) were estimated for each imaging risk group, subgroup, and pathological diagnosis. Time-dependent area-under-the receiver operating characteristic analysis (AUC) was used to compare the performance between imaging-based and pathology-based survival model.
RESULTS: Both OS and PFS were stratified according to the five imaging-based risk subgroups (P < 0.001) and three imaging-based risk groups (P < 0.001). The three imaging-based groups showed high performance in predicting PFS at one-year (AUC, 0.787) and five-years (AUC, 0.823), which was similar to that of the pathology-based prediction of PFS (AUC of 0.785 and 0.837). Combined with clinical predictors, the performance of the imaging-based survival model for 1- and 3-year PFS (AUC 0.813 and 0.921) was similar to that of the pathology-based survival model (AUC 0.839 and 0.889).
CONCLUSION: Imaging-based survival stratification according to the 2021 WHO classification demonstrated a performance similar to that of pathology-based survival stratification, especially in predicting PFS.
引用
- Lee SJ, Park JE, Park SY, et al. Imaging-Based Versus Pathologic Survival Stratifications of Diffuse Glioma According to the 2021 WHO Classification System. Korean J Radiol. 2023. PMID: 37500578. doi:10.3348/kjr.2022.0919
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。